Effects of Tuberculosis on the Kinetics of CD4 + T Cell Count Among HIV-Infected Patients Who Initiated Antiretroviral Therapy Early After Tuberculosis Treatment
Restricted accessResearch articleFirst published online February, 2013
Effects of Tuberculosis on the Kinetics of CD4 + T Cell Count Among HIV-Infected Patients Who Initiated Antiretroviral Therapy Early After Tuberculosis Treatment
The effects of tuberculosis (TB) on the kinetics of CD4+ T cells among HIV-infected individuals with early combination antiretroviral therapy (cART) after TB therapy initiation are poorly characterized. We conducted a case-control study with 15 HIV-TB-coinfected patients who initiated TB treatment and early cART, and 30 controls without TB who had similar CD4+ T cell counts and viral loads at the time of starting cART. We compared the rate of CD4+ T cell increase for 5 years after cART. The time to CD4+ T cell increase >250 cells/mm3 was significantly slower in HIV-TB-coinfected patients (p=0.015, by log rank test). HIV-TB-coinfected patients had significantly lower median CD4+ T cell counts at 5 years after cART (p=0.048). The difference in CD4+ T cell increase was observed only during the first 6 months after cART initiation (p=0.002). These data suggest that TB slows the rate of CD4+ T cell recovery at an early period after cART. The effects of TB on the long-term immunity of HIV-infected patients should be further evaluated.
Get full access to this article
View all access options for this article.
References
1.
ReidA, ScanoF, GetahunHet al.Towards universal access to HIV prevention, treatment, care, and support: The role of tuberculosis/HIV collaboration. Lancet Infect Dis, 2006; 6,8:483–495.
2.
KarimSS. Durban 2000 to Toronto 2006: The evolving challenges in implementing AIDS treatment in Africa. AIDS, 2006; 20,15:N7–9.
3.
AliyuMH, SalihuHM. Tuberculosis and HIV disease: Two decades of a dual epidemic. Wien Klin Wochenschr, 2003; 115,19–20:685–697.
4.
KizzaHM, RodriguezB, Quinones-MateuMet al.Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol, 2005; 12,11:1298–1304.
5.
WhalenCC, NsubugaP, OkweraAet al.Impact of pulmonary tuberculosis on survival of HIV-infected adults: A prospective epidemiologic study in Uganda. AIDS, 2000; 14,9:1219–1228.
6.
Lopez-GatellH, ColeSR, MargolickJBet al.Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS, 2008; 22,14:1869–1873.
7.
LancioniCL, MahanCS, JohnsonDFet al.Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis, 2011; 203,7:992–1001.
8.
ToossiZ, JohnsonJL, KanostRAet al.Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: Potential mechanisms of viral activation. J Acquir Immune Defic Syndr, 2001; 28,1:1–8.
9.
GolettiD, WeissmanD, JacksonRWet al.Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol, 1996; 157,3:1271–1278.
10.
HertogheT, WajjaA, NtambiLet al.T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB)Clin Exp Immunol, 2000; 122,3:350–357.
11.
ZhangM, GongJ, IyerDV, JonesBE, ModlinRL, BarnesPF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest, 1994; 94,6:2435–2442.
12.
Abdool KarimSS, NaidooK, GroblerAet al.Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med, 2010; 362,8:697–706.
13.
HavlirDV, KendallMA, IvePet al.Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med, 2011; 365,16:1482–1491.
14.
Abdool KarimSS, NaidooK, GroblerAet al.Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med, 2011; 365,16:1492–1501.
15.
WHO. Antiretroviral therapy for HIV infection in adults adolescents: Recommendations for a public health approach 2010 version. 2010.
16.
BissetLR, ConeRW, HuberWet al.Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS, 1998; 12,16:2115–2123.
17.
PlanaM, GarciaF, GallartTet al.Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS, 2000; 14,13:1921–1933.
18.
PakkerNG, NotermansDW, de BoerRJet al.Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med, 1998; 4,2:208–214.
19.
HermansSM, KiraggaAN, SchaeferP, KambuguA, HoepelmanAI, ManabeYC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One, 2010; 5,5:e10527.
20.
GazzolaL, TincatiC, BellistriGM, MonforteA, MarchettiG. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: Clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis, 2009; 48,3:328–337.
21.
HuntPW, MartinJN, SinclairEet al.T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis, 2003; 187,10:1534–1543.
22.
MarchettiG, GoriA, CasabiancaAet al.Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS, 2006; 20,13:1727–1736.
23.
HansjeeN, KaufmannGR, StrubC, WeberR, BattegayM, ErbP. Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J Acquir Immune Defic Syndr, 2004; 36,2:671–677.
24.
SmithCJ, SabinCA, LampeFCet al.The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS, 2003; 17,7:963–969.
25.
StaszewskiS, MillerV, SabinCet al.Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS, 1999; 13,8:951–956.
26.
BoulangerC, HollenderE, FarrellKet al.Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis, 2009; 49,9:1305–1311.
27.
ChouR, FuR, HuffmanLH, KorthuisPT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: Discrepancies between direct and indirect meta-analyses. Lancet, 2006; 368,9546:1503–1515.
28.
MacArthurRD, NovakRM, PengGet al.A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): A long-term randomised trial. Lancet, 2006; 368,9553:2125–2135.
29.
SpringerSA, FriedlandGH, DorosG, PesantiE, AlticeFL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials, 2007; 8,4:205–212.
